Synergy Pharma (NASDAQ:SGYP): Q3 GAAP EPS of -$0.14 in-line. • Revenue of $11.1M (+122.0% Y/Y) misses by $2.17M.
It’s all over. Revenue miss. My guess is SGYP will file bankruptcy over the weekend as they have a Nov 12 deadline. They surrendered the intellectual rights to the compounds to the financial firm. It is all spelled out on Seeking Alpha.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.